Eric S. Furfine
Chief Executive Officer at Mosaic Biosciences, Inc.
Network origin in Eric S. Furfine first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Extinct | Pharmaceuticals: Major | 19 | |
Mosaic Biosciences, Inc.
 Mosaic Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Mosaic Biosciences, Inc. provides commercial research and development services. It conducts research on synthetic materials that support native tissue regeneration. The firm's solutions are designed for application in wound healing, bone regeneration, cartilage repair, stem cell therapy, and dermal fillers. The company was founded by Martin Stanton, Chris Bowman, Kristi S. Anseth and Peter Mariner in 2009 and is headquartered in Boulder, CO.
6
| Holding Company | Miscellaneous Commercial Services | 6 |
Ingenia Therapeutics Inc.
 Ingenia Therapeutics Inc. Medical/Nursing ServicesHealth Services Ingenia Therapeutics, Inc. provides health care services. The company is headquartered in Cambridge, MA.
3
| Holding Company | Medical/Nursing Services | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Eric S. Furfine via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Sales & Marketing Director of Finance/CFO | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal | |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Pharmaceuticals: Generic | Corporate Officer/Principal | |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chief Executive Officer Chief Operating Officer Corporate Officer/Principal | |
| SATCON TECHNOLOGY CORPORATION | Semiconductors | Comptroller/Controller/Auditor | |
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| DYAX CORP. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member | |
| BRAINSTORM CELL THERAPEUTICS INC. | Biotechnology | Director/Board Member | |
| DNIB UNWIND INC | Biotechnology | Director/Board Member Chairman | |
| GELESIS INC | Biotechnology | Director/Board Member | |
HealthCare Ventures LLC
 HealthCare Ventures LLC Investment ManagersFinance HealthCare Ventures LLC (HealthCare Ventures) is a venture capital firm founded in 1985 by Harold R. Werner. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Consultant / Advisor | |
| BLUEBIRD BIO, INC. | Biotechnology | Director/Board Member Chairman | |
| University of Cambridge | College/University | Doctorate Degree Doctorate Degree | |
| Massachusetts Institute of Technology | College/University | Director/Board Member Doctorate Degree | |
| The University of Colorado | College/University | Undergraduate Degree Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| University of Vermont | College/University | Undergraduate Degree | |
Tel-Aviv University
 Tel-Aviv University Other Consumer ServicesConsumer Services Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel. | College/University | Masters Business Admin | |
Teva Pharmaceuticals USA, Inc.
 Teva Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Teva Pharmaceuticals USA, Inc. engages in the manufacturing and marketing of generic pharmaceuticals. The firm also provides medical affairs, quality plus safety and trade partner services. The company was founded in 1985 and is headquartered in Parsippany, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
National Academy of Engineering
 National Academy of Engineering Miscellaneous Commercial ServicesCommercial Services Part of The National Academies of Science, the National Academy of Engineering operates as a professional membership organization. The company is based in Washington. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Wyeth Research
 Wyeth Research Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Wyeth Research discovers and develops platforms encompassing pharmaceuticals. The company is based in Cambridge, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| CONSTELLATION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | President Corporate Officer/Principal | |
New England Eye Center
 New England Eye Center Medical/Nursing ServicesHealth Services New England Eye Center offers a full range of ophthalmology services. It specializes in cornea, external disease, and cataracts; glaucoma; oculoplastics; pediatric ophthalmology; retinal and macular diseases; vision rehabilitation; uveitis and immunology; pediatric optometry; and vision correction surgery. The company is headquartered in Boston, MA. | Medical/Nursing Services | Director/Board Member Corporate Officer/Principal | |
Alliance for Cancer Gene Therapy, Inc.
 Alliance for Cancer Gene Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Alliance for Cancer Gene Therapy, Inc. provides funding for cancer research. The non-profit company is based in Stamford, CT. The company was founded by Edward Netter. Kevin Honeycutt has been the CEO of the company since 2018. | Miscellaneous Commercial Services | Director/Board Member | |
Edimer Pharmaceuticals, Inc.
 Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| KARYOPHARM THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member | |
| Arthur Anderson & Co. | Corporate Officer/Principal | ||
Protein Technologies, Inc.
 Protein Technologies, Inc. Medical SpecialtiesHealth Technology Protein Technologies, Inc. engages in the design, manufacture and supply of solid phase synthesizers. The company was founded in 1985 and is headquartered in Tucson, AZ. | Medical Specialties | Corporate Officer/Principal | |
| BLUEPRINT MEDICINES CORPORATION | Biotechnology | Chairman Chairman | |
| University of Haifa | College/University | Undergraduate Degree | |
T1D Exchange
 T1D Exchange Pharmaceuticals: MajorHealth Technology T1D Exchange is a nonprofit organization that was established in 2010 with initial and ongoing support from the Leona M. and Harry B. Helmsley Charitable Trust. T1D Exchange is based in Boston, MA. The non-profit company is dedicated to improving outcomes for the entire T1D population through real-world evidence and clinical data collection and analysis. T1D Exchange is a leading provider of real-world evidence, identifying gaps in data and redefining best practices to improve the lives of those living with T1D. The company actively supports quality improvement and innovation through its quality improvement collaborative, patient registry, and data-oriented research services. David Walton has been the CEO of the company since 2018. | Pharmaceuticals: Major | Director/Board Member | |
| VOYAGER THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chief Executive Officer Director of Finance/CFO | |
| Tufts University School of Medicine | College/University | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Unitio, Inc.
 Unitio, Inc. Internet Software/ServicesTechnology Services Unitio, Inc. operates a platform for the healthcare industry. | Internet Software/Services | Director/Board Member | |
Rheos Medicines, Inc.
 Rheos Medicines, Inc. BiotechnologyHealth Technology Rheos Medicines, Inc. operates as a biopharmaceutical firm. It develops novel medicines that modulate metabolic pathways in immune cells to treat disease. The company was founded by Erika Pearce, Edward Pearce, Laurence Turka, Richard Flavell, Ken Smith, and E. William St. Clair and is headquartered in Cambridge, MA. | Biotechnology | Chairman | |
Cedilla Therapeutics, Inc.
 Cedilla Therapeutics, Inc. BiotechnologyHealth Technology Cedilla Therapeutics, Inc. operats as a biotechnology company. It engages in discovering and exploiting insights into protein stability. The company was founded by Alan D. D?Andrea, Steve Gygi, Matthew P. Jacobson, William G. Kaelin, Jr. and Jack Taunton on September 6, 2017 and is headquartered in Cambridge, MA. | Biotechnology | Chairman | |
Flare Therapeutics, Inc.
 Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Biotechnology | Chairman | |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor Corporate Officer/Principal Private Equity Investor Corporate Officer/Principal | |
Abata Therapeutics, Inc.
 Abata Therapeutics, Inc. BiotechnologyHealth Technology Abata Therapeutics, Inc. is a biotech company based in Watertown, MA. Abata Therapeutics is focused on developing engineered Treg cell therapies for severe autoimmune and inflammatory diseases. The American company's lead programs are in ind-enabling studies for progressive multiple sclerosis and type 1 diabetes, both of which are tissue-specific autoimmune diseases with significant unmet needs. The company has developed a differentiated product engine to create tissue-specific, robust, and durable therapies. Abata Therapeutics was launched by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara Biocapital, and the JDRF T1D Fund. The company was founded in 2021 by Richard Ransohoff and the CEO is Samantha Singer. | Biotechnology | Chairman | |
Carbon Biosciences, Inc.
 Carbon Biosciences, Inc. Medical/Nursing ServicesHealth Services Carbon Biosciences, Inc. is a biotech company that is based in Boston, MA. The company is focused on expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. The company is working to expand the gene therapy toolbox for the treatment of the world's most devastating and difficult to treat diseases. Carbon was founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D. | Medical/Nursing Services | Chairman |
Statistics
International
| United States | 45 |
| Israel | 5 |
| United Kingdom | 2 |
| Switzerland | 2 |
Sectoral
| Health Technology | 32 |
| Consumer Services | 7 |
| Finance | 5 |
| Commercial Services | 5 |
| Health Services | 3 |
Operational
| Director/Board Member | 212 |
| Corporate Officer/Principal | 88 |
| Chairman | 61 |
| Founder | 58 |
| Independent Dir/Board Member | 54 |
Most connected contacts
| Insiders | |
|---|---|
| Noubar Afeyan | 76 |
| Augustine Lawlor | 43 |
| Daniel Lynch | 32 |
| Mark Levin | 26 |
| Wendy Dixon | 25 |
| Jane Henderson | 25 |
| Burt Adelman | 23 |
| Abbie Celniker | 23 |
| Chen Schor | 23 |
| Cameron Wheeler | 20 |
| Mark T. Lupa | 18 |
| Gregory Perry | 16 |
| Karen L. Tubridy | 13 |
| Michael H. Goldstein | 12 |
| Paul Chaney | 12 |
- Stock Market
- Insiders
- Eric S. Furfine
- Company connections
